Adherence to chronic hepatitis B treatment guideline recommendations for laboratory monitoring of patients who are not receiving antiviral treatment

Journal of General Internal Medicine

Volumn 26, Issue 3, 2011, Pages 239-244

  Juday, Timothy ^a   Tang, Hong ^a   Harris, Melissa ^a   Powers, Annette Z ^a,b   Kim, Edward ^a,b   Hanna, George J ^a  

^a BRISTOL MYERS SQUIBB   (United States)

^b EISAI INC   (United States)

Author keywords

alanine aminotransferase; antiviral therapy; hepatitis B virus DNA; initiation; treatment guidelines

Indexed keywords

ALANINE AMINOTRANSFERASE; HEPATITIS B SURFACE ANTIGEN; VIRUS DNA;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIVIRAL THERAPY; ARTICLE; CLINICAL ASSESSMENT TOOL; DEYO CHARLSON COMORBIDITY INDEX; FEMALE; HEALTH CARE PLANNING; HEALTH CARE QUALITY; HEALTH SERVICE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; LABORATORY DIAGNOSIS; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; PATIENT MONITORING; PRACTICE GUIDELINE; PREDICTIVE VALUE; SEX DIFFERENCE; TREATMENT PLANNING;

ADOLESCENT; ADULT; AGED; ANTIVIRAL AGENTS; COHORT STUDIES; DNA, VIRAL; FEMALE; FOLLOW-UP STUDIES; GUIDELINE ADHERENCE; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VACCINES; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; LABORATORY TECHNIQUES AND PROCEDURES; MALE; MIDDLE AGED; PRACTICE GUIDELINES AS TOPIC; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 79953680455     PISSN: 08848734     EISSN: 15251497     Source Type: Journal    
DOI: 10.1007/s11606-010-1549-9     Document Type: Article

References (29)

1. BJ McMahon 2005 Epidemiology and natural history of hepatitis B Semin Liver Dis 25 Suppl 1 3 8 10.1055/s-2005-915644 16103976 (Pubitemid 41254588)
2. MF Sorrell EA Belongia J Costa, et al. 2009 National Institutes of Health Consensus Development Conference Statement: management of hepatitis B Ann Intern. Med 150 104 110 19124811
3. SJ Hadziyannis NC Tassopoulos EJ Heathcote, et al. 2006 Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years Gastroenterology 131 1743 1751 1:CAS:528:DC%2BD2sXhtFyltLs%3D 10.1053/j.gastro.2006.09.020 17087951 (Pubitemid 44958517)
4. HJ Yim AS Lok 2006 Natural history of chronic hepatitis B virus infection: what we knew in 1981 and what we know in 2005 Hepatology 43 S173 S181 1:CAS:528:DC%2BD28XhvVSktbk%3D 10.1002/hep.20956 16447285
5. AS Lok BJ McMahon 2009 Chronic hepatitis B: update 2009 Hepatology 50 661 662 10.1002/hep.23190 19714720
6. Institute of Medicine. Hepatitis and Liver Cancer. A National Strategy for Prevention and Control of Hepatitis B and C. Available at: http://books.nap.edu/openbook.php?record-id=12793&page=R1 (accessed September 2010).
7. American Association for the Study of Liver Diseases. The Route from the IOM to Public Health Passes through AASLD. AASLD News; May 6, 2010. Available at: http://www.aasld.org/journals/archive/050610/Pages/default.aspx (accessed September 2010).
8. Liaw YF, Sung JJ, Chow WC, et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med. 2004;351:1521-31.
9. Gish RG. Hepatitis B treatment: Current best practices, avoiding resistance. Cleve. Clin J Med. 2009;76 Suppl 3:S14-9.
10. D Widjaja S Yarlagadda BS Singu, et al. 2007 Characteristics of patients with chronic hepatitis-B virus infection in an urban hospital J Natl. Med Assoc 99 384 388 17444427 (Pubitemid 46608863)
11. EG Giannini F Torre M Basso, et al. 2009 A significant proportion of patients with chronic hepatitis B who are candidates for antiviral treatment are untreated: A region-wide survey in Italy J Clin Gastroenterol. 43 1001 1007 10.1097/MCG.0b013e31818e876f 19318981
12. Wolters Kluwer Pharma Solutions, Inc. Chronic Hepatitis B, Total Prescription Sales Data, Sep 2009-Feb 2010. Philadelphia, PA, March 2010.
13. CJ Chen HI Yang J Su, et al. 2006 Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level JAMA. 295 65 73 1:CAS:528:DC%2BD28XhtlKqtQ%3D%3D 10.1001/jama.295.1.65 16391218 (Pubitemid 43042691)
14. UH Iloeje HI Yang J Su CL Jen SL You CJ Chen 2006 Predicting cirrhosis risk based on the level of circulating hepatitis B viral load Gastroenterology 130 678 686 10.1053/j.gastro.2005.11.016 16530509 (Pubitemid 43374518)
15. UH Iloeje HI Yang CL Jen, et al. 2007 Risk and predictors of mortality associated with chronic hepatitis B infection Clin Gastroenterol Hepatol 5 921 931 10.1016/j.cgh.2007.06.015 17678844 (Pubitemid 47161142)
16. G Chen W Lin F Shen UH Iloeje WT London AA Evans 2006 Past HBV viral load as predictor of mortality and morbidity from HCC and chronic liver disease in a prospective study Am J Gastroenterol 101 1797 1803 10.1111/j.1572-0241.2006. 00647.x 16817842 (Pubitemid 44166589)
17. CJ Liu BF Chen PJ Chen, et al. 2006 Role of hepatitis B viral load and basal core promoter mutation in hepatocellular carcinoma in hepatitis B carriers J Infect Dis 193 1258 1265 1:CAS:528:DC%2BD28Xkslanu7k%3D 10.1086/502978 16586363
18. K Ohata K Hamasaki K Toriyama H Ishikawa K Nakao K Eguchi 2004 High viral load is a risk factor for hepatocellular carcinoma in patients with chronic hepatitis B virus infection J Gastroenterol Hepatol 19 670 675 10.1111/j.1440-1746.2004.03360.x 15151623 (Pubitemid 38858201)
19. MW Yu SH Yeh PJ Chen, et al. 2005 Hepatitis B virus genotype and DNA level and hepatocellular carcinoma: a prospective study in men J Natl. Cancer Inst. 97 265 272 1:CAS:528:DC%2BD2MXhsFSns78%3D 10.1093/jnci/dji043 15713961 (Pubitemid 40310274)
20. S Chevaliez JM Pawlotsky 2009 Virological techniques for the diagnosis and monitoring of hepatitis B and C Ann Hepatol 8 7 12 1:CAS:528: DC%2BD1MXitlKjuro%3D 19221527
21. European Association For The Study Of The Liver 2009 EASL Clinical Practice Guidelines. Management of chronic hepatitis B J Hepatol 50 227 242 10.1016/j.jhep.2008.10.001
22. YF Liaw N Leung JH Kao, et al. 2008 Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update Hepatol Int 2 263 283 10.1007/s12072-008-9080-3 19669255
23. EB Keeffe DT Dieterich SH Han, et al. 2008 A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: 2008 update Clin Gastroenterol Hepatol 6 1315 1341 1:CAS:528:DC%2BD1MXhtFSlurk%3D 10.1016/j.cgh.2008.08.021 18845489
24. D Prati E Taioli A Zanella, et al. 2002 Updated definitions of healthy ranges for serum alanine aminotransferase levels Ann Intern. Med 137 1 10 1:CAS:528:DC%2BD38Xls1entbc%3D 12093239
25. D Mitra KL Davis C Beam J Medjedovic V Rustgi 2010 Treatment patterns and adherence among patients with chronic hepatitis C virus in a US managed care population Value Health 13 479 86 10.1111/j.1524-4733.2009.00691.x 20102555
26. ML Berger M Mamdani D Atkins ML Johnson 2009 Good research practices for comparative effectiveness research: defining, reporting and interpreting nonrandomized studies of treatment effects using secondary data sources: the ISPOR Good Research Practices for Retrospective Database Analysis Task Force report-part I Value Health 12 1044 52 10.1111/j.1524-4733.2009.00600.x 19793072
27. International Classification of Diseases, 9th Revision, Clinical Modification. 5th edition Medicode Publications, Salt Lake City UT, 1997.
28. RA Deyo DC Cherkin MA Ciol 1992 Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases J Clin Epidemiol. 45 613 619 1:STN:280:DyaK38zgtVeqsA%3D%3D 10.1016/0895-4356(92)90133-8 1607900
29. DB Rein SB Lesesne PJ Leese CM Weinbaum 2010 Community-based hepatitis B screening programs in the United States in 2008 J Viral Hepat 17 28 33 1:STN:280:DC%2BC3c%2FhtVGrsA%3D%3D 10.1111/j.1365-2893.2009.01165.x 19674286